Imagion Biosystems Ltd has released a press release.
2022 R&D Tax Refund
Filed with ASX ·
6ix hasn’t read this filing yet.
Imagion Biosystems Ltd. on 6ix
Story so far
Earlier from Imagion Biosystems
- Appendix 4D
- Half-Year Results Release
- Non-renounceable Entitlement Offer Shortfall
- Imagion to complete the MagSense HER2 Phase 1 Study
- Imagion Announces New CEO
Later from Imagion Biosystems
- Imagion presents ovarian cancer data at AACR conference
- Notice of Extraordinary General Meeting/Proxy Form
- Phase 1 Study Closure and Preliminary Performance
- Imagion Announces Positive Results from Phase 1 Study
- Imagion Announces CEO Departure
Follow Imagion Biosystems into a list and get an email when it puts out news.
Follow Imagion Biosystems